REGN22044 / Regeneron - LARVOL DELTA

REGN22044: A FULLY HUMAN IL-12P35 ANTIBODY POTENTLY AND SPECIFICALLY INHIBITS IL-12 (AASLD 2026) - "These data highlight specific suppression of the IL-12 pathway as a compelling therapeutic target in AIH and PBC. REGN22044 binds to IL-12p35 with high affinity and potently and specifically inhibits IL-12 signaling in vitro and in vivo, supporting its potential as a novel approach to the treatment of PBC and AIH."

Autoimmune Hepatitis • Hepatology • Immunology • Inflammation • Primary Biliary Cholangitis • IFNG • IL12A • IL23A • TBX21

A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting | N=64 ➔ 88 | Trial completion date: May 2027 ➔ Feb 2027 | Trial primary completion date: May 2027 ➔ Feb 2027

Enrollment change • Enrollment open • First-in-human • Trial completion date • Trial primary completion date